Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae .
Pınar Aysert-YildizÖzge Özgen-TopHamid HabibiMurat DizbayPublished in: Journal of chemotherapy (Florence, Italy) (2022)
The aim of the study was to evaluate clinical and microbiological efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant K. pneumoniae infections. All adult inpatients receiving 48 h of intravenous fosfomycin, alone or combined with other antibiotics were included in the study. Overall favorable clinical response rate was 75.3% among 94 patients. Clinical response rates were 92.3%, 72.2% and 56.0% for urinary tract infections, bacteremia and pneumonia, respectively. Microbiological eradication was achieved in 55 of 86 patients. 30-day mortality was 33.0%. Adverse events were generally mild. Common adverse events were hypokalemia (37.2%) and hypernatremia (22.3%). Intravenous fosfomycin is an effective antibiotic option with a good safety profile for the treatment of carbapenem-resistant K. pneumoniae infections. The most favorable clinical and microbiological responses are obtained in urinary tract infections. The efficacy of the drug in more severe infections, such as pneumonia and bacteremia, is comparable to the literature.
Keyphrases
- urinary tract infection
- gram negative
- klebsiella pneumoniae
- high dose
- multidrug resistant
- end stage renal disease
- escherichia coli
- systematic review
- chronic kidney disease
- type diabetes
- emergency department
- ejection fraction
- intensive care unit
- newly diagnosed
- cardiovascular disease
- coronary artery disease
- helicobacter pylori
- patient reported outcomes
- helicobacter pylori infection